0001140361-19-009718.txt : 20190523
0001140361-19-009718.hdr.sgml : 20190523
20190523105339
ACCESSION NUMBER: 0001140361-19-009718
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190522
FILED AS OF DATE: 20190523
DATE AS OF CHANGE: 20190523
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 19848523
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
3
1
form3.xml
FORM 3
X0206
3
2019-05-22
0
0001761612
BICYCLE THERAPEUTICS Ltd
BCYC
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX
X0
TW8 9GS
UNITED KINGDOM
true
true
Series A Preferred Shares
Ordinary Shares
893195
I
See Explanation of Response
Series B1 Preferred Shares
Ordinary Shares
636366
I
See Explanation of Response
The Series A Preferred Shares are convertible at any time at the election of the holder without payment of further consideration. Each share of Series A Preferred Shares will automatically convert into 1.429 shares of ordinary shares upon the closing of Bicycle Therapeutics Limited's (the "Issuer") initial public offering. The shares have no expiration date.
Share numbers give effect to the bonus shares issued to each holder of ordinary shares on the basis of 1.429 bonus shares for each ordinary share in issue, effective on May 13, 2019, which will be effective for the ordinary shares upon their conversion to ordinary shares upon the closing of the Issuer's initial public offering.
The Series B1 Preferred Shares are convertible at any time at the election of the holder without payment of further consideration. Each share of B1 Preferred Shares will automatically convert into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering. The shares have no expiration date.
The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
/s/ Victoria Whyte For and on behalf of GlaxoSmithKline plc
2019-05-22